Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
NCT06116461
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
34
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
Nivolumab
Sponsor
Erasmus Medical Center